-+ 0.00%
-+ 0.00%
-+ 0.00%

EPICRISPR BIOTECHNOLOGIES CLOSES $90 MILLION OVERSUBSCRIBED SERIES C FINANCING TO ADVANCE FIRST-IN-CLASS EPIGENETIC THERAPY TOWARD PIVOTAL STUDIES IN FSHD

Reuters·08/11/2026 12:03:03

Please log in to view news